Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway.
Animals
Cardiotoxicity
/ drug therapy
Cardiotoxins
/ adverse effects
Doxorubicin
/ adverse effects
Male
Mice
Myocytes, Cardiac
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Rutin
/ pharmacology
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ metabolism
cardiomyocytes
cardiotoxicity effect
pirarubicin
rutin
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
28 06 2019
28 06 2019
Historique:
received:
06
03
2019
revised:
26
03
2019
accepted:
03
05
2019
pubmed:
30
5
2019
medline:
30
7
2020
entrez:
30
5
2019
Statut:
epublish
Résumé
Cancer is the leading cause of deaths around the world, especially in low- and middle- income countries. Pirarubicin (THP) is an effective drug for treatment of cancer, however, there still exists cardiotoxic effects of THP. Rutin is a kind of antioxidative compound extracted from plants, and might be a protective compound for cardiomyocytes. Phosphatidylinositol 3-hydroxy kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is critical for cellular survival, proliferation and metabolism, and thus we speculated rutin might perform a protective role in cardiomyocytes via PI3K/AKT/mTOR signaling pathway. And in this experiment, we first established a cardiotoxicity model of THP in mice model and cell models, and then found that rutin treatment could increase the proliferation of cells at low concentration. Then we explored the possible mechanism of the protective effect of rutin using Western blotting, quantitative polymerase chain reaction (qPCR) and ELISA methods, and found that the activation of PI3K/AKT/mTOR/nuclear factor-κB (NF-κB) signaling pathway was increased, and expression of downstream molecules involved in antioxidative stress were also increased. We further noticed that concentration of angiogenesis promoting factors were also increased in medium of cultured cells. Thus, we speculated that rutin could increase the activation of PI3K/AKT/mTOR signaling pathway, further decrease the oxidative stress level via increasing the expression of antioxidative stress enzymes with the increasing concentration of angiogenesis promoting factors, resulting in the protective role in cardiomyocytes and cardiac function.
Identifiants
pubmed: 31138757
pii: BSR20190546
doi: 10.1042/BSR20190546
pmc: PMC6591567
pii:
doi:
Substances chimiques
Cardiotoxins
0
Rutin
5G06TVY3R7
Doxorubicin
80168379AG
pirarubicin
D58G680W0G
mTOR protein, mouse
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 The Author(s).
Références
J Clin Invest. 2006 Nov;116(11):2955-63
pubmed: 17053836
Biochim Biophys Acta. 2005 Jan 17;1703(2):231-8
pubmed: 15680231
Front Pharmacol. 2013 May 07;4:57
pubmed: 23675348
Development. 1992 May;115(1):11-20
pubmed: 1638975
Med Pediatr Oncol. 1994;22(4):261-8
pubmed: 8107658
PLoS One. 2011;6(11):e26390
pubmed: 22069448
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
Front Physiol. 2015 Jul 07;6:194
pubmed: 26217233
PLoS One. 2011;6(12):e29058
pubmed: 22216167
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Int J Mol Sci. 2015 Feb 02;16(2):3202-12
pubmed: 25648320
Dig Dis. 2019;37(5):406-415
pubmed: 30783074
J Antibiot (Tokyo). 1979 Oct;32(10):1082-4
pubmed: 528373
Free Radic Biol Med. 2005 Jun 15;38(12):1543-52
pubmed: 15917183
J Biol Chem. 1994 Nov 4;269(44):27670-8
pubmed: 7961686
J Agric Food Chem. 1999 Nov;47(11):4649-52
pubmed: 10552865
Biochem Pharmacol. 2001 Sep 15;62(6):743-6
pubmed: 11551519
Int J Mol Sci. 2019 Mar 06;20(5):
pubmed: 30845718
J Clin Oncol. 2010 Jun 20;28(18):2974-81
pubmed: 20479407
Sci Signal. 2019 Feb 26;12(570):
pubmed: 30808818
Biochim Biophys Acta. 2009 Jan;1795(1):37-52
pubmed: 18778756
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Oncotarget. 2014 Apr 15;5(7):1897-911
pubmed: 24722367
Diabetes. 2010 Jan;59(1):51-60
pubmed: 19794062
Cell Death Differ. 1999 Feb;6(2):99-104
pubmed: 10200555
Br J Cancer. 1995 Mar;71(3):518-24
pubmed: 7880733
Br J Cancer. 2014 Sep 23;111(7):1327-37
pubmed: 25101566
Evid Based Complement Alternat Med. 2017;2017:1759385
pubmed: 28367221
Cancer Prev Res (Phila). 2012 Apr;5(4):631-43
pubmed: 22369852
Int Immunopharmacol. 2018 Jun;59:310-317
pubmed: 29679855
Biochimie. 2002 Feb-Mar;84(2-3):203-14
pubmed: 12022951
Circulation. 2001 Nov 27;104(22):2673-8
pubmed: 11723017
Antioxid Redox Signal. 2011 Aug 1;15(3):781-94
pubmed: 20919930
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77
pubmed: 19234476
Cell Rep. 2017 Mar 7;18(10):2464-2479
pubmed: 28273460
Mol Cell Biol. 1992 Dec;12(12):5447-54
pubmed: 1448077
Cancer Sci. 2010 Aug;101(8):1866-74
pubmed: 20579075
Exp Anim. 2017 Oct 30;66(4):417-423
pubmed: 28701621
Pharm Res. 2013 Nov;30(11):2940-50
pubmed: 23783345
Nat Commun. 2015 Jan 29;6:6184
pubmed: 25630468
Nature. 2012 May 17;485(7398):391-4
pubmed: 22522926
Genes Dev. 1996 May 15;10(10):1184-93
pubmed: 8675006
J Exp Med. 2008 Jun 9;205(6):1303-15
pubmed: 18474628
Trends Cardiovasc Med. 2005 Oct;15(7):254-9
pubmed: 16226680